

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7253067

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	VICTOR W. ROSSO	03/25/2022
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	BRISTOL-MYERS SQUIBB COMPANY	
<b>Street Address:</b>	ROUTE 206 AND PROVINCE LINE ROAD	
<b>Internal Address:</b>	PATENT DEPARTMENT	
<b>City:</b>	PRINCETON	
<b>State/Country:</b>	NEW JERSEY	
<b>Postal Code:</b>	08543	
<b>PROPERTY NUMBERS Total: 2</b>		
	<b>Property Type</b>	<b>Number</b>
	<b>Application Number:</b>	17587374
	<b>PCT Number:</b>	US2214261
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(609)252-4526	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	6092524741	
<b>Email:</b>	patents@bms.com	
<b>Correspondent Name:</b>	ELLIOTT KORSEN	
<b>Address Line 1:</b>	ROUTE 206 AND PROVINCE LINE ROAD	
<b>Address Line 2:</b>	PATENT DEPARTMENT	
<b>Address Line 4:</b>	PRINCETON, NEW JERSEY 08543	
<b>ATTORNEY DOCKET NUMBER:</b>	13890-US-NP/WO	
<b>NAME OF SUBMITTER:</b>	FIDELIZ ROMERO	
<b>SIGNATURE:</b>	/fideliz romero/	
<b>DATE SIGNED:</b>	03/30/2022	
<b>Total Attachments: 2</b>		
source=2022025_ASG_13890USNP_WO_VR#page1.tif		
source=2022025_ASG_13890USNP_WO_VR#page2.tif		

ASSIGNMENT

I,

**Victor W. Rosso**


pursuant to contractual obligations heretofore assumed by us and/or for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell and assign and/or confirm the sale and assignment to Bristol-Myers Squibb Company, a Delaware corporation, having a place of business at Rt. 206 & Province Line Road, Princeton, NJ 08543, and its successors, assigns and legal representatives, of all our right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to us by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention entitled:

**CRYSTAL FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D<sub>3</sub>) PYRIDAZINE-3-CARBOXAMIDE**

invented by us and described in the non-provisional United States Patent Application Number **17/587374**, filed **28 January 2022**, and PCT International Patent Application Number **PCT/US2022/14261**, filed **28 January 2022**,

including said non-provisional United States patent application and PCT International Patent Application and any patent application claiming priority from above identified patent applications, filed in any country, and any patents which may be issued and/or granted thereon, and all divisions, continuations, reissues, reexamination certificates and extensions thereof in all countries, said interest being the entire ownership of said invention and all of said patent applications, patents (including reissue patents), extensions and reexamination certificates to be held and enjoyed by Bristol-Myers Squibb Company and its successors and assigns to the full end of the terms to which said patents (including reissue patents), extensions and reexamination certificates may be granted and/or issued, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made;

And we hereby agree to communicate to said assignee or its representatives any facts known to us respecting said invention, to testify in any legal proceedings, to sign and/or execute any further documents and/or instruments which may be necessary, lawful and proper in and/or for the filing and/or prosecution of all patent applications, including divisional, continuation and reissue applications, extensions and reexamination certificates and/or the granting and/or issuance thereof and/or to otherwise secure title to said invention and all of said patent applications, patents (including reissue patents), extensions and reexamination certificates in said assignee, and in general to do everything possible to aid said assignee and its successors and assigns to obtain and enforce proper protection for said invention in all countries.

Signed this 25 day of March, 2022, by   
Victor W. Rosso